{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:54:36Z","timestamp":1793044476485,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.jhep.2016.09.008","type":"journal-article","created":{"date-parts":[[2016,9,24]],"date-time":"2016-09-24T23:50:27Z","timestamp":1474761027000},"page":"338-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":353,"title":["The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma"],"prefix":"10.1016","volume":"66","author":[{"given":"David J.","family":"Pinato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Allara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarence","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaaki","family":"Arizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Bettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Won","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Smirne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Woon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Ramaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela E.","family":"Burlone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Thimme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Stebbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Pirisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian I.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.09.008_b0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhep.2016.09.008_b0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000218339","article-title":"Hepatocellular carcinoma\u2013epidemiological trends and risk factors","volume":"27","author":"Schutte","year":"2009","journal-title":"Dig Dis"},{"key":"10.1016\/j.jhep.2016.09.008_b0015","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jhep.2008.01.022","article-title":"Novel advancements in the management of hepatocellular carcinoma in 2008","volume":"48","author":"Llovet","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.09.008_b0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1055\/s-2008-1040325","article-title":"Assessment of prognosis of cirrhosis","volume":"28","author":"Durand","year":"2008","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2016.09.008_b0025","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1365-2036.2005.02691.x","article-title":"Systematic review: The model for end-stage liver disease\u2013should it replace Child-Pugh\u2019s classification for assessing prognosis in cirrhosis?","volume":"22","author":"Cholongitas","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.09.008_b0030","first-page":"73","article-title":"Are there any alternative methods to hepatic venous pressure gradient in portal hypertension assessment?","volume":"22","author":"Procopet","year":"2013","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.jhep.2016.09.008_b0035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jhep.2015.08.025","article-title":"Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma","volume":"64","author":"Cucchetti","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.09.008_b0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/gast.2003.50016","article-title":"Model for end-stage liver disease (MELD) and allocation of donor livers","volume":"124","author":"Wiesner","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.09.008_b0045","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/lt.20824","article-title":"A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation","volume":"12","author":"Cholongitas","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2016.09.008_b0050","doi-asserted-by":"crossref","first-page":"11567","DOI":"10.3748\/wjg.v21.i41.11567","article-title":"Non-invasive diagnosis of liver fibrosis and cirrhosis","volume":"21","author":"Lurie","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.09.008_b0055","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.cgh.2013.07.034","article-title":"Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"11","author":"Singh","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.09.008_b0060","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2016.09.008_b0065","doi-asserted-by":"crossref","first-page":"ii24","DOI":"10.1093\/annonc\/mdt054","article-title":"Intermediate hepatocellular carcinoma: current treatments and future perspectives","volume":"24","author":"Dufour","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2016.09.008_b0070","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.09.008_b0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2016.09.008_b0080","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2012.06.022","article-title":"A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI)","volume":"57","author":"Pinato","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.09.008_b0085","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/cncr.24884","article-title":"Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study","volume":"116","author":"Carr","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2016.09.008_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.11.037","article-title":"Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification","volume":"13","author":"Pinato","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.09.008_b0095","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2016.09.008_b0100","series-title":"Team RC. R: A language and environment for statistical computing","year":"2014"},{"key":"10.1016\/j.jhep.2016.09.008_b0105","doi-asserted-by":"crossref","unstructured":"Harrell FE. Regression Modeling Strategies. 3.0 ed; 2010.","DOI":"10.32614\/CRAN.package.rms"},{"key":"10.1016\/j.jhep.2016.09.008_b0110","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jhep.2015.10.029","article-title":"Prognosis of hepatocellular carcinoma: assessment of eleven staging systems","volume":"64","author":"Liu","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.09.008_b0115","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S0168-8278(12)60009-9","article-title":"Management of HCC","volume":"56","author":"de Lope","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.09.008_b0120","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1055\/s-0034-1394142","article-title":"Transarterial chemoembolization and radioembolization","volume":"34","author":"Sangro","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2016.09.008_b0125","first-page":"348","article-title":"Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions","volume":"32","author":"Bolondi","year":"2012","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2016.09.008_b0130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-2005-871198","article-title":"Resection and liver transplantation for hepatocellular carcinoma","volume":"25","author":"Llovet","year":"2005","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2016.09.008_b0135","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1586\/14737140.2016.1123625","article-title":"Curative therapies for hepatocellular carcinoma: an update and perspectives","volume":"16","author":"Sacco","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jhep.2016.09.008_b0140","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/jgh.13250","article-title":"Usefulness of albumin-bilirubin (ALBI) grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma","volume":"31","author":"Hiraoka","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.09.008_b0145","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/jgh.13291","article-title":"Integration of albumin-bilirubin (ALBI) score into Barcelona clinic liver cancer (BCLC) system for hepatocellular carcinoma","volume":"31","author":"Chan","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.09.008_b0150","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/annonc\/mdt247","article-title":"A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer","volume":"24","author":"Kadalayil","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2016.09.008_b0155","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/apt.12992","article-title":"Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study","volume":"40","author":"Pinato","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2016.09.008_b0160","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2014.07.002","article-title":"How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma","volume":"61","author":"Hucke","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.09.008_b0165","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mds343","article-title":"Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis","volume":"24","author":"Pressiani","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2016.09.008_b0170","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3892\/mco.2015.536","article-title":"Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma","volume":"3","author":"Lg","year":"2015","journal-title":"Mol Clin Oncol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816305359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816305359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T17:12:35Z","timestamp":1749575555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816305359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0168827816305359"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.09.008","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}